Daymark Wealth Partners LLC Has $6.18 Million Holdings in Pfizer Inc. (NYSE:PFE)

Daymark Wealth Partners LLC trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 9.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 243,733 shares of the biopharmaceutical company's stock after selling 25,397 shares during the quarter. Daymark Wealth Partners LLC's holdings in Pfizer were worth $6,176,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the fourth quarter valued at $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.3%

Shares of NYSE PFE traded up $0.07 during mid-day trading on Wednesday, reaching $24.37. The company had a trading volume of 23,123,588 shares, compared to its average volume of 40,970,416. The stock has a market capitalization of $138.55 billion, a PE ratio of 17.29, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock's 50 day moving average is $22.93 and its 200-day moving average is $24.98.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the business posted $0.82 earnings per share. The business's quarterly revenue was down 7.8% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.06%. Pfizer's payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Finally, UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.